Verdera Energy Corp announced its registration statement was approved by the SEC, allowing enCore Energy to distribute 35 million Verdera common shares to its shareholders as a special dividend on September 30, 2026. This follows a 2025 agreement where enCore received non-voting preferred shares convertible into common shares. The distribution requires final approvals from Nasdaq and TSX Venture Exchange and includes transfer restrictions on some shares. This move supports Verdera's focus on uranium development in New Mexico and offers enCore shareholders direct equity in Verdera.
Verdera Energy's SEC registration statement approval is noted here with market context from Pluang's Basic Materials sector. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 15, 2026 16:51 WIB: out of 32 priced US stocks, 10 rose and 20 fell. Notable prices include FCX at USD 67.82 (-2.21%), SLI at USD 2.13 (+1.91%), and BHP at USD 83.35 (-1.64%).
Inflation rose 3.4% over the past year, while the average savings account pays only 0.38% APY, causing most cash savings to lose value. Moving money to a high-yield savings account paying around 4.00% APY can help your savings grow faster than inflat...
Rubrik (RBRK) offers an advanced AI-driven cybersecurity SaaS platform showing robust subscription growth (+33% YoY), high net revenue retention (>119%), and expanding profit margins. Despite a strong Rule of 53.4%, the stock trades at a reasonable E...
Standard Chartered initiated coverage of Arbitrum's ARB token with a price target of $10 by the end of 2030, implying a roughly 70-fold increase from its current price of around $0.13. The bank highlights revenue potential from enterprise chains like...
Solana has upgraded its mainnet to increase the maximum transaction size from 1,232 bytes to 4,096 bytes, allowing developers to include more complex instructions and data in a single transaction. This change supports advanced features like zero-know...
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with...
